Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

2.

G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.

Gunaratnam M, Green C, Moreira JB, Moorhouse AD, Kelland LR, Moses JE, Neidle S.

Biochem Pharmacol. 2009 Jul 15;78(2):115-22.

PMID:
19475728
3.

Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.

Hegmans A, Kasparkova J, Vrana O, Kelland LR, Brabec V, Farrell NP.

J Med Chem. 2008 Apr 10;51(7):2254-60. doi: 10.1021/jm070813z. Epub 2008 Mar 14.

4.

Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents.

Martins C, Gunaratnam M, Stuart J, Makwana V, Greciano O, Reszka AP, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2293-8. Epub 2007 Jan 25.

PMID:
17276687
5.

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Zhao L, Marshall ES, Kelland LR, Baguley BC.

Invest New Drugs. 2007 Jun;25(3):271-6. Epub 2007 Jan 3.

PMID:
17203401
6.

Discovery and development of anticancer aptamers.

Ireson CR, Kelland LR.

Mol Cancer Ther. 2006 Dec;5(12):2957-62. Review.

7.

Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol.

Nicoll K, Robertson J, Lant N, Kelland LR, Rogers PM, Robins DJ.

Oncol Res. 2006;16(2):97-106.

PMID:
16898270
9.

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GC, Martin NM, Workman P, Raynaud FI.

Br J Cancer. 2005 Oct 31;93(9):1011-8.

10.
11.

Small molecule anticancer drugs.

Kelland LR.

IDrugs. 1999 Jun;2(6):550-2.

PMID:
16127615
12.
13.

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P.

Clin Cancer Res. 2005 Jul 1;11(13):4875-87.

14.

Emerging drugs for ovarian cancer.

Kelland LR.

Expert Opin Emerg Drugs. 2005 May;10(2):413-24. Review.

PMID:
15934876
15.

Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.

McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP.

Clin Cancer Res. 2005 May 15;11(10):3705-13.

17.
18.

Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding.

Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5845-9.

PMID:
15501053
19.

A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.

Incles CM, Schultes CM, Kempski H, Koehler H, Kelland LR, Neidle S.

Mol Cancer Ther. 2004 Oct;3(10):1201-6.

20.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.

Cancer Res. 2004 Sep 15;64(18):6693-9.

21.

Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.

Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.

Anticancer Res. 2004 Mar-Apr;24(2B):907-19.

22.
23.

Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH.

J Med Chem. 2004 Mar 25;47(7):1856-9.

PMID:
15027879
24.

Variation in RNA expression and genomic DNA content acquired during cell culture.

Hiorns LR, Bradshaw TD, Skelton LA, Yu Q, Kelland LR, Leyland-Jones B.

Br J Cancer. 2004 Jan 26;90(2):476-82.

25.

Bioreductive prodrugs for cancer therapy.

Seddon B, Kelland LR, Workman P.

Methods Mol Med. 2004;90:515-42. Review. No abstract available.

PMID:
14657582
27.

Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.

Harrison RJ, Cuesta J, Chessari G, Read MA, Basra SK, Reszka AP, Morrell J, Gowan SM, Incles CM, Tanious FA, Wilson WD, Kelland LR, Neidle S.

J Med Chem. 2003 Oct 9;46(21):4463-76.

PMID:
14521409
28.

Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.

Pearson VC, Ferguson J, Rogers PM, Kelland LR, Robins DJ.

Oncol Res. 2003;13(11):503-12.

PMID:
12812364
29.

Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.

Urbaniak MD, Frost LM, Bingham JP, Kelland LR, Hartley JA, Woolfson DN, Caddick S.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):2025-7.

PMID:
12781188
30.

Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics.

McSheehy PM, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR.

Eur J Cancer. 2003 Mar;39(4):532-40.

PMID:
12751386
31.

Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].

PĂ©rez JM, Kelland LR, Montero EI, Boxall FE, Fuertes MA, Alonso C, Navarro-Ranninger C.

Mol Pharmacol. 2003 Apr;63(4):933-44.

PMID:
12644595
32.

Farnesyl transferase inhibitors in the treatment of breast cancer.

Kelland LR.

Expert Opin Investig Drugs. 2003 Mar;12(3):413-21. Review.

PMID:
12605564
33.

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.

Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR.

Eur J Cancer. 2002 Nov;38(17):2309-15.

PMID:
12441268
34.
35.

ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR.

Anticancer Res. 2002 Jul-Aug;22(4):1993-9.

PMID:
12174876
36.
37.
38.

Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug.

Berry JM, Howard PW, Kelland LR, Thurston DE.

Bioorg Med Chem Lett. 2002 May 20;12(10):1413-6.

PMID:
11992788
39.

A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.

Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR.

Mol Pharmacol. 2002 May;61(5):1154-62.

PMID:
11961134
40.

Telomerase: biology and phase I trials.

Kelland LR.

Lancet Oncol. 2001 Feb;2(2):95-102. Review.

PMID:
11905801
41.

Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.

Rogers PM, Beale PJ, Al-Moundhri M, Boxall F, Patterson L, Valenti M, Raynaud F, Hobbs S, Johnston S, Kelland LR.

Int J Cancer. 2002 Feb 20;97(6):858-63.

42.

Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts.

Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, Kelland LR, Stevens MF.

J Med Chem. 2002 Jan 31;45(3):590-7.

PMID:
11806711
43.

Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen.

Lant NJ, McKeown P, Timoney MC, Kelland LR, Rogers PM, Robins DJ.

Anticancer Drug Des. 2001 Feb;16(1):49-55.

PMID:
11762644
44.

High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance.

Cocker HA, Hobbs SM, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR.

Br J Cancer. 2001 Nov 30;85(11):1746-52.

45.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR.

Clin Cancer Res. 2001 Nov;7(11):3544-50.

46.
47.

Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes.

Gowan SM, Heald R, Stevens MF, Kelland LR.

Mol Pharmacol. 2001 Nov;60(5):981-8.

PMID:
11641426
48.

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

Smith V, Raynaud F, Workman P, Kelland LR.

Mol Pharmacol. 2001 Nov;60(5):885-93.

PMID:
11641415
49.

Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer.

Gregson SJ, Howard PW, Corcoran KE, Jenkins TC, Kelland LR, Thurston DE.

Bioorg Med Chem Lett. 2001 Nov 5;11(21):2859-62.

PMID:
11597416
50.

In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.

Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR.

Clin Cancer Res. 2001 Oct;7(10):3193-8.

Supplemental Content

Loading ...
Support Center